MVP Stock Overview
Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Medical Developments International Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.42 |
| 52 Week High | AU$1.08 |
| 52 Week Low | AU$0.38 |
| Beta | 1.53 |
| 11 Month Change | -5.56% |
| 3 Month Change | -8.60% |
| 1 Year Change | -46.20% |
| 33 Year Change | -91.63% |
| 5 Year Change | -93.84% |
| Change since IPO | -11.46% |
Recent News & Updates
Recent updates
Positive Sentiment Still Eludes Medical Developments International Limited (ASX:MVP) Following 27% Share Price Slump
May 13
Is Medical Developments International (ASX:MVP) In A Good Position To Invest In Growth?
May 03Why Investors Shouldn't Be Surprised By Medical Developments International Limited's (ASX:MVP) 28% Share Price Plunge
Mar 11Medical Developments International Limited (ASX:MVP) Soars 28% But It's A Story Of Risk Vs Reward
Jan 16Will Medical Developments International (ASX:MVP) Spend Its Cash Wisely?
Jan 03Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?
Aug 09We're Keeping An Eye On Medical Developments International's (ASX:MVP) Cash Burn Rate
Apr 24Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?
Jul 04Some Analysts Just Cut Their Medical Developments International Limited (ASX:MVP) Estimates
Mar 04Medical Developments International Limited (ASX:MVP) Analysts Just Slashed This Year's Estimates
Mar 05If You Had Bought Medical Developments International (ASX:MVP) Shares Five Years Ago You'd Have Earned 56% Returns
Feb 07Don't Ignore The Fact That This Insider Just Sold Some Shares In Medical Developments International Limited (ASX:MVP)
Dec 16Medical Developments International Limited's (ASX:MVP) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?
Dec 10
Shareholder Returns
| MVP | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -3.4% | -11.8% | 1.5% |
| 1Y | -46.2% | 39.8% | 17.2% |
Return vs Industry: MVP underperformed the Australian Pharmaceuticals industry which returned 39.8% over the past year.
Return vs Market: MVP underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| MVP volatility | |
|---|---|
| MVP Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: MVP has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: MVP's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | n/a | Brent MacGregor | medicaldev.com |
Medical Developments International Limited manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It offers Penthrox, a trauma and emergency pain relief product for use in hospitals, emergency departments, ambulance services, sport medicines, and for analgesia during short procedures.
Medical Developments International Limited Fundamentals Summary
| MVP fundamental statistics | |
|---|---|
| Market cap | AU$47.88m |
| Earnings (TTM) | -AU$40.99m |
| Revenue (TTM) | AU$33.15m |
1.4x
P/S Ratio-1.2x
P/E RatioIs MVP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MVP income statement (TTM) | |
|---|---|
| Revenue | AU$33.15m |
| Cost of Revenue | AU$8.78m |
| Gross Profit | AU$24.37m |
| Other Expenses | AU$65.36m |
| Earnings | -AU$40.99m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 73.50% |
| Net Profit Margin | -123.66% |
| Debt/Equity Ratio | 0% |
How did MVP perform over the long term?
See historical performance and comparison